Structured evidence table for Probiotic Eczema Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotic Eczema Randomized Trial | Based on the available evidence, moisturizers and probiotics in infancy appear to have the most benefit in the primary prevention of AD compared to other interventions. | 3 | Kiszluk A (2026) | The State of Prevention of Atopic Dermatitis: An Updated Review. |
| Probiotic Eczema Randomized Trial | Atopic dermatitis (AD) is a chronic inflammatory skin disorder that has a high worldwide prevalence and carries substantial psychosocial and financial burden. | 3 | Kiszluk A (2026) | The State of Prevention of Atopic Dermatitis: An Updated Review. |
| Probiotic Eczema Randomized Trial | In this review, we provide an update synthesizing relevant clinical trials published from January 2020 through July 2025. | 3 | Kiszluk A (2026) | The State of Prevention of Atopic Dermatitis: An Updated Review. |
| Probiotic Eczema Randomized Trial | Figure 1 Supplementary material 3: Tables 1–4 There were no significant differences between the treatment groups regarding disease severity, as assessed by EASI and IGA, TEWL, or patient-reported QoL-associated parameters, including pruritus and sleep disturbance VAS scores, DLQI, POEM, and ADCT. | 4 | Salo Ville (2026) | Topical probiotic Lactobacillus lactis treatment in atopic dermatitis: a placebo-controlled pilot study on tolerability and efficacy |
| Probiotic Eczema Randomized Trial | p p p Table 2 QoL-associated parameters did not change significantly during the study period and were similar in all patient groups. | 4 | Salo Ville (2026) | Topical probiotic Lactobacillus lactis treatment in atopic dermatitis: a placebo-controlled pilot study on tolerability and efficacy |
| Probiotic Eczema Randomized Trial | AD severity parameters, TEWL, and patient-reported QoL-associated parameters were similar in the placebo group and probiotic lysate groups. | 4 | Salo Ville (2026) | Topical probiotic Lactobacillus lactis treatment in atopic dermatitis: a placebo-controlled pilot study on tolerability and efficacy |
| Probiotic Eczema Randomized Trial | 1 2 3 4 5 6 7 9 Staphylococcus aureus Atopic dermatitis (AD) is one of the most frequent skin disorders in developed countries and affects approximately 10–20% of the adult Finnish population (). | 4 | Salo Ville (2026) | Topical probiotic Lactobacillus lactis treatment in atopic dermatitis: a placebo-controlled pilot study on tolerability and efficacy |
Source documents